539
Participants
Start Date
December 31, 2005
Primary Completion Date
April 30, 2008
Study Completion Date
April 30, 2008
Retigabine
Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
Retigabine
Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
Placebo
Oral tablet.
Natl. Inst. of Psychiatry and Neurology, Budapest
Orszagos Idegsebeszeti Tudomanyos Intezet, Budapest
Centre Neurologique William Lennox, Ottignies
A. Z. Middelheim -- Department of Neurology, Antwerp
Royal Prince Alfred Hospital, Camperdown
Sunninghill & Kopano Clinical Trials, Sunninghill
Johannesburg Hospital, Johannesburg
Universitaire Ziekenhuizen Gasthuisberg -- Department Neurology, Leuven
Royal Melbourne Hospital, Parkville
Austin & Repatriation Medical Centre, West Heidelberg
Monash Medical Centre, Clayton
Inkosi Albert Luthuli Central Hospital, Durban
North Coast Neurology Centre, Maroochydore
Triple M Research, Port Elizabeth
Carl Bremer Hospital, Belville
Panorama Medi-Clinic, Cape Town
Groote Schuur Hospital, Cape Town
AZ Sint-Jan, Bruges
University of the Free State, Bloemfontein
Hosp. Virgen de las Nieves, Granada
Hosp de Donostia, Donostia / San Sebastian
Mid-Atlantic Epilepsy and Sleep Center, Bethesda
Western Galilee Hospital, Nahariya
Hospital Ruber Internacional de Madrid, Madrid
Rambam Medical Center, Haifa
CHU Pontchaillou, Rennes
Hospital de Cruces, Bilbao
Psychosomatic Center of Dnepropetr. Regional Clinic, Dnipro
Hosp. Clinico Univ. Lozano Blesa, Zaragoza
Chaim Sheba Medical Center, Ramat Gan
Wolfson Medical Center, Holon
Kharkiv State Medical University, Kharkiv
Institute of Neurology, Psychiatry and Narcology of AMS, Ukr, Kharkiv
Tel-Aviv Sourasky Medical Center, Tel Aviv
Odessa Regional Clinical Hospital, Odesa
Hopital Neurologique Pierre Wertheimer, Lyon
Assaf Harofeh Medical Center, Beer Yaakov
Neurological Clinic-Texas, Dallas
Kaplan Medical Center, Rehovot
Barzilai Medical Center, Ashkelon
City Hospital # 1, Moscow
Clinic of Nervous Diseases of Sechenov's Moscow Med. Academy, Moscow
District Antiepileptic Centre City Clinical Hospital # 71, Moscow
Military Medical Academy n.a. S.M.Kirov, Saint Petersburg
St.Petersburg State Medical University n.a. I.P.Pavlov, Saint Petersburg
Interregional Clinical Diagnostic Centre, Kazan'
Hopital Civil de Strasbourg, Strasbourg
Centre Medical de La Teppe, Tain-l'Hermitage
University of Bonn -- Department for Epileptplogy, Bonn
Zentrum Epilepsie Erlangen (ZEE) der Universitaet Erlangen, Erlangen
Georg-August-Universitaet Goettingen, Göttingen
Universitaetsklinik Mainz Neurologische Klinik, Mainz
Universitaet Giessen / Marburg Neurologie, Marburg
Theatinerstrasse 44, Munich
Universitaetsklinikum Ulm, Ulm
Specjalistyczna Przychodnia Lekarska Medikard, Padlewskiego 4
"NZOZ Przychodnia Internistyczno - Stomatologiczna Kendron", Bialystok
Wojewodzki Szpital Specjalistyczny im.Mikolaja Kopernika, Gdansk
Katedra i Klinika Neurologii Slaskiej Akademii Medycznej, Katowice
WSS im.Kardynala S. Wyszynskiego, Lublin
Instytut Psychiatrii i Neurologii II Oddzial Neurologii, Warsaw
"Prywatna Wielospecjalistyczna Lecznica Medyczna Zycie", Warsaw
Wilgers MR & Medical Centre, Pretoria
Hospital de La Santa Creu i Sant Pau, Barcelona
Epilepsy Center of Municipal Clinical Psychoneurological Hospital, Kiev
The James Cook University Hospital, Middlesbrough
Fylde Coast Hospital, Blackpool
Western Infirmary (Epilepsy), Glasgow
Walton Centre for Neurology & Neurosurgery, Liverpool
Royal London Hospital, London
Lead Sponsor
Bausch Health Americas, Inc.
INDUSTRY
GlaxoSmithKline
INDUSTRY